RiverPoint Capital Management LLC raised its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 2.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,759 shares of the company’s stock after purchasing an additional 255 shares during the quarter. RiverPoint Capital Management LLC’s holdings in AbbVie were worth $780,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ABBV. Acropolis Investment Management LLC purchased a new stake in shares of AbbVie in the second quarter worth about $106,000. Franklin Parlapiano Turner & Welch LLC purchased a new stake in shares of AbbVie in the first quarter worth about $108,000. Atwood & Palmer Inc. lifted its holdings in shares of AbbVie by 1,333.3% in the first quarter. Atwood & Palmer Inc. now owns 2,150 shares of the company’s stock worth $140,000 after buying an additional 2,000 shares in the last quarter. Tradewinds Capital Management LLC lifted its holdings in shares of AbbVie by 87.2% in the first quarter. Tradewinds Capital Management LLC now owns 2,269 shares of the company’s stock worth $148,000 after buying an additional 1,057 shares in the last quarter. Finally, Exane Asset Management purchased a new stake in shares of AbbVie in the second quarter worth about $181,000. 68.16% of the stock is currently owned by institutional investors and hedge funds.
AbbVie Inc. (ABBV) opened at $94.75 on Wednesday. The company has a quick ratio of 1.32, a current ratio of 1.45 and a debt-to-equity ratio of 5.08. AbbVie Inc. has a fifty-two week low of $58.60 and a fifty-two week high of $98.26. The stock has a market cap of $151,852.42, a P/E ratio of 17.91, a PEG ratio of 1.32 and a beta of 1.51.
The company also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be issued a $0.71 dividend. This is a boost from AbbVie’s previous quarterly dividend of $0.64. The ex-dividend date of this dividend is Thursday, January 11th. This represents a $2.84 annualized dividend and a dividend yield of 3.00%. AbbVie’s dividend payout ratio (DPR) is currently 62.29%.
ABBV has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded shares of AbbVie from a “buy” rating to a “hold” rating in a research note on Friday, October 20th. BidaskClub raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday. BMO Capital Markets set a $66.00 target price on shares of AbbVie and gave the company a “hold” rating in a research note on Friday, October 27th. SunTrust Banks, Inc. reaffirmed a “buy” rating on shares of AbbVie in a research note on Monday, October 30th. Finally, Leerink Swann lowered their target price on shares of AbbVie from $108.00 to $107.00 and set an “outperform” rating on the stock in a research note on Monday, October 30th. Eight equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $93.68.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.themarketsdaily.com/2017/11/15/riverpoint-capital-management-llc-acquires-255-shares-of-abbvie-inc-abbv.html.
In related news, EVP Michael Severino sold 25,633 shares of the firm’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $94.69, for a total value of $2,427,188.77. Following the completion of the sale, the executive vice president now owns 114,922 shares of the company’s stock, valued at $10,881,964.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Azita Saleki-Gerhardt sold 8,300 shares of the firm’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $85.02, for a total value of $705,666.00. Following the completion of the sale, the senior vice president now directly owns 93,099 shares of the company’s stock, valued at approximately $7,915,276.98. The disclosure for this sale can be found here. Insiders sold 58,932 shares of company stock valued at $5,379,432 in the last ninety days. 0.23% of the stock is currently owned by insiders.
AbbVie Company Profile
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV).
Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.